Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Recommendation of “Hold” from Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given an average recommendation of “Hold” by the twenty ratings firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $123.33.

A number of equities research analysts have recently commented on the stock. Wolfe Research began coverage on shares of Zimmer Biomet in a research note on Tuesday, September 10th. They set a “peer perform” rating on the stock. Barclays cut their price objective on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday, December 12th. Canaccord Genuity Group dropped their target price on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 10th. Oppenheimer reduced their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. Finally, Wells Fargo & Company raised their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st.

Institutional Trading of Zimmer Biomet

A number of hedge funds and other institutional investors have recently modified their holdings of ZBH. American Century Companies Inc. increased its position in Zimmer Biomet by 12.6% during the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock worth $701,521,000 after purchasing an additional 722,041 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after buying an additional 125,852 shares during the period. Van ECK Associates Corp lifted its holdings in Zimmer Biomet by 12.4% in the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after acquiring an additional 411,163 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Zimmer Biomet by 0.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,569,311 shares of the medical equipment provider’s stock worth $277,357,000 after acquiring an additional 9,990 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Zimmer Biomet by 9.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,810,770 shares of the medical equipment provider’s stock valued at $196,523,000 after purchasing an additional 154,447 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 0.0 %

NYSE:ZBH opened at $104.47 on Friday. The firm has a market capitalization of $20.80 billion, a P/E ratio of 19.86, a PEG ratio of 1.96 and a beta of 1.02. The company’s fifty day moving average price is $108.37 and its 200-day moving average price is $108.17. Zimmer Biomet has a 1-year low of $101.47 and a 1-year high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $1.65 EPS. As a group, equities research analysts anticipate that Zimmer Biomet will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.